Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Surufatinib |
| Synonyms | |
| Therapy Description |
Surufatinib (HMPL-012) is a dual VEGFR/FGFR1 inhibitor, which potentially results in reduced cell proliferation and migration, alteration of the tumor microenvironment, and inhibition of tumor angiogenesis and growth (PMID: 37361567). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Surufatinib | Sulfatinib|HMPL-012 | FGFR1 Inhibitor 28 VEGFR Inhibitor (Pan) 36 | Surufatinib (HMPL-012) is a dual VEGFR/FGFR1 inhibitor, which potentially results in reduced cell proliferation and migration, alteration of the tumor microenvironment, and inhibition of tumor angiogenesis and growth (PMID: 37361567). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04814732 | Expanded access | Surufatinib | Expanded Access Program of Surufatinib | No longer available | USA | 0 |
| NCT02549937 | Phase I | Surufatinib | A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors | Completed | USA | ITA | 0 |
| NCT04579679 | Phase II | Surufatinib | Open-Label Surufatinib in European Patients With NET | Terminated | USA | NOR | ITA | GBR | FRA | ESP | DEU | 0 |